Hold Rating for Teladoc Amid UpLift Acquisition and Adjusted EBITDA Guidance Revision

Charles Rhyee, an analyst from TD Cowen, maintained the Hold rating on Teladoc (TDOC – Research Report). The associated price target remains the same with $8.00.

Charles Rhyee’s rating is based on a combination of factors including Teladoc’s recent acquisition of UpLift and the subsequent revision of its 2025 adjusted EBITDA guidance. The updated guidance reflects the anticipated impact of UpLift, which is expected to contribute to revenue but also incur an EBITDA loss. Additionally, investments aimed at accelerating the insurance business and anticipated user attrition in the U.S. Behavioral Health segment have been factored into the estimates.
Furthermore, Rhyee’s analysis considers the projected revenue growth in Integrated Care, which aligns with management’s guidance, despite a slight decline in adjusted EBITDA margin. In the BetterHelp segment, a year-over-year revenue decline is expected, although it remains within the company’s guidance. The acquisition of UpLift is projected to have a negative impact on the Behavioral Health adjusted EBITDA, and international revenue is anticipated to grow significantly. These elements collectively support the Hold rating, with a maintained price target based on a discounted cash flow analysis.

In another report released on May 1, Bank of America Securities also reiterated a Hold rating on the stock with a $8.00 price target.